• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Positron emission tomography
 

Positron emission tomography

on

  • 1,624 views

PET is a scanning technique used in combination with small amounts of radio-labeled compounds to visualize the anatomy and function of the brain. The purpose of this TriMark Publications report is to ...

PET is a scanning technique used in combination with small amounts of radio-labeled compounds to visualize the anatomy and function of the brain. The purpose of this TriMark Publications report is to describe the specific market segment of the diagnostics medical imaging market called PET scanning.

Statistics

Views

Total Views
1,624
Views on SlideShare
1,624
Embed Views
0

Actions

Likes
0
Downloads
17
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Positron emission tomography Positron emission tomography Document Transcript

    • Positron Emission Tomography (PET) MarketsPublished: July 2011No. of Pages: 225Price: $3400The medical imaging segments are poised for a major new phase of growth fueled by theavailability of new technology coming out of the computer and digital informationtechnology segment. Continuous improvements in technology are resulting in a growingnumber of new imaging tests that combine high levels of accuracy with rapid, easy-to-useproduct formats. Part of that medical imaging improvement is coming from positronemission tomography (PET) markets.PET is a scanning technique used in combination with small amounts of radio-labeledcompounds to visualize the anatomy and function of the brain. The purpose of this TriMarkPublications report is to describe the specific market segment of the diagnostics medicalimaging market called PET scanning. This sector includes all of the generally acceptedimaging activities that are currently used in PET, including equipment for PET, PET/CT,SPECT and the use of radiopharmaceuticals for imaging. It examines these clinicalmeasurement devices and their reagents and supplies as used in hospitals and clinics. Italso reviews associated clinical market segments in which PET scanning has taken aprominent role including cancer treatment, cardiology, and neurology imaging markets.1. Overview1.1 Scope of This Report1.2 Methodology1.3 Executive Summary2. PET Technology: An Overview2.1 History and Development of PET2.1.1 Early Beginnings2.1.2 The 1950s: Pioneering Ideas for PET2.1.3 The 1960s and 1970s: The Development of PET2.1.4 The 1980s: PETs Advancement and Performance in Research Sector
    • 2.1.5 The 1990s: PETs Progression in the Clinical Sector2.1.5.1 PET Advancements of the 1990s2.1.5.2 PETS Ability to Identify Pathophysiology2.1.5.3 Insurance Coverage for PET2.1.5.4 Availability of FDG2.1.6 The 2000s: PET/CT Scanner2.1.7 The Working of PET2.1.8 Coincidence Detection2.1.9 Coincidence Imaging2.1.10 PET Modes2.1.11 Obstacles to Widespread Use of PET2.1.12 Dedicated PET Equipment2.2 PETs Comparison with Other Conventional Imaging Procedures2.3 Trends in PET Instrumentation2.3.1 Advances in PET/CT Imaging2.3.2 Promise of PET/MR Imaging2.4 Cost Considerations in PET Scanners2.5 Economics of Hybrid Systems2.5.1 Hybrid Optimization2.5.2 Image Quality and Hybrids3. PET Applications: An Overview3.1 Applications of PET and PET/CT in Oncology3.1.1 PET/CTs Growth in Clinical Oncology in the U.S. and Europe3.1.2 Cancer: Global Incidence and Mortality3.1.3 PET: The Most Powerful Imaging Tool in Cancer Management3.1.4 Increases in Cancer Imaging Costs3.1.5 New Criteria for Diagnosing Alzheimers disease3.1.6 Expanded Applications for PET in Oncology3.1.6.1 PET Scanning for Prostate Cancer3.1.6.2 PET/CT in Radiation Treatment Planning for Cancer Patient Treatment3.1.6.3 PET in Radiation Therapy Planning3.1.6.4 Imaging Protocols for PET in Radiation Therapy Planning3.2 Applications of PET in Cardiology3.2.1 Cost of Cardiovascular Disease3.2.2 CVD: The Single Largest Killer in Adults3.2.3 Prevalence of CVD in the U.S.3.2.4 Economic Cost of CVD in the U.S.3.2.5 PET: The Established Diagnostic Tool in Cardiology3.2.6 PET and Heart Disease Diagnosis3.2.7 PET/CTs Suitability in Cardiac Imaging3.2.8 Need for Dedicated PET Devices for Cardiac Imaging3.2.9 Impact of PET in Reducing Biopsies3.2.10 Current Status of Nuclear Medicine in Cardiology
    • 3.2.10.1 Current Status of Cardiac Nuclear Medicine in Asia3.2.10.2 Current Status of Cardiac Nuclear Medicine in Europe3.2.10.3 Current Status of Cardiac Nuclear Medicine in Latin America3.2.10.4 Current Status of Cardiac Nuclear Medicine in North America3.2.11 SPECT vs. PET in Cardiology3.3 Application of PET in Neurology3.3.1 PETs Promising Role in Diagnosing Migraines and schizophrenia3.3.2 PETs key role in Parkinsons research3.3.3 PETs Prediction on Surgical Outcome in Refractory Epilepsy Patients3.3.4 Disease-Specific Applications of PET and PET/CT in Neurology3.3.4.1 PET Imaging of Brain Tumors3.3.4.2 PET and Brain Metastases3.3.4.3 PET in Dementia3.3.4.4 PET in Epilepsy4. PET Radioisotopes and Radiopharmaceuticals4.1 Types of Radiopharmaceuticals4.1.1 Diagnostic Radiopharmaceuticals4.1.2 Suppliers of Radiopharmaceuticals4.1.3 Radioisotopes Used in Medicine4.1.4 Cyclotron Radioisotopes4.1.5 FDA-Approved Radiopharmaceuticals4.1.6 Some Common Radiopharmaceuticals in PET Imaging4.1.6.1 Nitrogen-13 Ammonia4.1.6.2 Rubidium-824.1.6.3 Oxygen-15 Water4.1.6.4 Flourine-18 fluorodeoxyglucose (FDG)4.1.7 Generator-Produced PET Radiopharmaceuticals4.1.8 New PET Agents for Cardiology4.1.8.1 New Neuronal Imaging Agents5. Market Analysis5.1 Global Market for Medical Imaging Modalities5.1.1 Global Medical Imaging Market Share by Modality, 20105.2 PET and PET/CT Market5.2.1 Pet and PET/CTs Application Areas5.2.1.1 Global Spending on Cancer5.2.1.2 U.S. Spending on Cancer and Cancer Imaging5.2.1.3 U.K. Spending on Cancer5.2.2 Global Market for Diagnostic Imaging Equipment for Oncology5.2.2.1 Improved Diagnosis and Staging by Technological Advances5.2.2.2 Importance of Imaging to Cancer Treatment5.2.2.3 PET/CT Market in Oncology Sector5.2.2.4 Percent Share of PET/CT Utilization by Type of Cancer
    • 5.2.2.5 The Lions Share of PET/CT Imaging in Oncology5.2.3 Economic Evaluation of PET and PET/CT in Oncology5.2.3.1 Costs for PET and PET/CT in Oncology5.2.3.2 Cost Effectiveness of PET and PET/CT in Selected Cancer Types5.2.3.3 Cost Effectiveness in the diagnosis of Solitary Pulmonary Nodules5.2.3.4 Cost Effectiveness in the Detection of Non-Small Lung Cancer5.2.3.5 Cost Effectiveness in the Detection of Colorectal Cancer5.2.3.6 Cost Effectiveness in the Detection of Head and Neck Cancers5.2.3.7 Cost Effectiveness in the Detection of Malignant Lymphoma5.2.3.8 Cost Effectiveness in the Detection of Pancreatic cancer5.2.3.9 Cost Effectiveness in the Detection of Other Solid Neoplasms5.2.4 PET/CT: Business Models5.2.4.1 The Models5.2.4.2 Market Forces5.2.5 Rising Demand for PET5.2.5.1 Changes in PET Reimbursement5.2.5.2 Initial Results from the National Oncologic PET Registry (NOPR)5.2.5.3 The Road toward Open Coverage for PET5.2.6 Future of SPECT and PET5.3 Imaging Markets in Cardiology5.3.1 Nuclear Imaging of Heart5.3.2 Global Utilization of Nuclear Imaging in Cardiology5.3.2.1 Future of Global Nuclear Cardiology Utilization5.3.2.2 Utilization of Nuclear Cardiology Procedures in Developed Countries5.3.2.3 Utilization of Nuclear Cardiology Procedures in Latin America5.3.2.4 Utilization of Nuclear Cardiology Procedures in Asia/Oceania5.3.2.5 Utilization of Nuclear Cardiology in Africa5.3.2.6 Utilization of Nuclear Cardiology and Mortality Rate5.3.2.7 Cost-Effectiveness in Nuclear Cardiology5.3.2.8 Epidemiology of Cardiovascular Diseases in Developing Countries5.3.3 Global Opportunities for Nuclear Cardiology Products5.3.3.1 Competition in Nuclear Cardiology Market5.3.4 Need for Dedicated PET Imaging in Cardiology5.3.5 Market for PET Imaging Systems5.3.5.1 Growth Rate for PET Cameras5.3.5.2 The Decline of SPECT and the Rise of PET5.3.5.3 Dedicated PET vs. Hybrid PET5.3.5.4 The Different Paths of SPECT/CT and PET/CT5.3.6 U.S. PET Landscape5.3.6.1 PET and PET/Studies in the U.S. for Oncology5.3.6.2 PET/CT Studies in the U.S. for Cardiology5.3.6.3 PET/CT Studies in the U.S. for Neurologic Studies5.3.6.4 U.S. Growth Rate for PET Procedure Volume5.3.7 Utilization of PET Scanners in the U.S. Finger Lakes Region
    • 5.3.7.1 U.S. PET Utilization by Body Site5.3.7.2 PET Utilization by Payment Type5.3.7.3 U.S. PET Utilization Rates5.3.7.4 U.S. Demand for SPECT, SPECT/CT, PET and PET/CT5.3.8 U.S: Cardiac PET Payments5.3.8.1 Opposition for Reduction5.3.8.2 Breakeven Point5.3.9 CMS Coverage for Cancer Patients and PET/CT Growth5.3.9.1 Opportunities for the Providers of PET and PET/CT5.3.10 Medicare Reimbursement for PET Procedures5.3.10.1 Coding5.3.10.2 Reimbursement5.3.10.3 Payment for Diagnostic Radiopharmaceuticals5.3.11 U.S. Market for PET5.3.12 PET Landscape across Canada5.3.13 PET scanning in Canada5.3.13.1 Publicly Funded PET Scanning in Canada5.3.13.2 Privately Funded PET Scanning in Canada5.3.13.3 Utilization of PET in Ontario5.3.13.4 CVD: Number One Killer in Canada5.3.14 PET Landscape in Europe5.3.14.1 PET Installations in Europe5.3.14.2 Growth of PET/CT in the E.U. Market5.3.14.3 PET/CT Procedures in Europe5.3.14.4 Locations of PET Centers in Europe5.3.14.5 PET Studies per Million Population in Europe5.3.14.6 The Commercial Isotope Market in Europe5.3.15 Availability of PET in U.K5.3.15.1 PET Units in Europe5.3.15.2 Cyclotron-Based Isotopes5.3.15.3 Nuclear Imaging Leaders in Europe5.3.15.4 European Market for PET/CT5.3.15.5 Nuclear Imaging System Market in Germany5.3.15.6 Nuclear Imaging Market in France5.3.15.7 U.K. Nuclear Imaging System Market5.3.15.8 Nuclear Imaging System Market in Italy5.3.15.9 PET Services in Europe5.3.15.10 PET Services in England5.3.15.11 Availability of PET in U.K5.3.16 Costs of Setting up a PET Center in U.K. with a Distant Supply of Tracer5.3.16.1 Capital Costs5.3.16.2 Operating Costs5.3.16.3 Fixed Costs5.3.16.4 Variable Costs
    • 5.3.16.5 Costs of Setting up a PET Center in U.K. with Full Production of Tracer5.3.16.6 Operating Costs5.3.16.7 Staff Costs5.3.16.8 Radiotracer Production5.3.16.9 Fixed Costs5.3.16.10 Variable Costs5.3.16.1 Radiotracer Production5.3.17 Nuclear Medicine Equipment and Consumables in India5.3.17.1 Market Trends5.3.17.2 Key Market Drivers5.3.18 Status of PET in India5.3.18.1 Historic Perspective5.3.18.2 The Isotope5.3.18.3 FDG Supply5.3.18.4 Ownership of Cyclotron5.3.18.5 Issues of the Cyclotron5.3.18.6 Regulation for Cyclotron and Isotope Supply5.3.18.7 Cyclotron Supply Issue5.3.18.8 Isotope within the End User Site5.3.18.9 Hardware Issues5.3.18.10 Indications for PET Studies in India5.3.18.11 Indian Nuclear Medicine Equipment Market5.4 Nuclear Medicine5.4.1 Shortage of Isotopes for Medical Imaging5.4.2 The Supply of Medical Radioisotopes5.4.3 Isotopes Used in PET Imaging5.4.4 Isotopes Used in SPECT Imaging5.4.5 Rapid Growth of Radiotracers5.4.6 Global Market for Mo-99/Tc-99m5.4.6.1 Global Market for Mo-99 by Geography5.4.6.2 Global demand for Tc-99m5.4.6.3 Market Trends for Tc-99m5.4.6.4 Supply Uncertainties5.4.6.5 Pricing5.4.6.6 Impact of Tc-99m Pricing on Health Care Budgets5.4.7 Impact of Technetium Shortage5.4.7.1 Global Impact5.4.7.2 Popular Medical Uses of Tc-99m5.4.7.3 Market Trends for Tc-99m5.4.7.4 Supply Uncertainties5.4.7.5 Pricing5.4.7.6 Impact of Tc-99m Pricing on Health Care Budgets5.4.8 18F-fluorodeoxyglucose (FDG) Positron Emission tomography (PET)5.4.9 FDG Utilization in Europe
    • 5.4.10 Future of Radiopharmaceuticals5.4.11 U.S. Radioisotopes Industry5.4.11.1 Industry Trends and Developments5.4.11.2 Market Trends for Radiopharmaceuticals and Brachytherapy5.4.11.3 Supply Disruptions5.4.11.4 U.S. Shipments, Consumption and Trade5.4.11.5 U.S. Trade of Radioisotopes5.4.11.6 U.S. Exports of Radioisotopes5.4.11.7 U.S. Imports of Radioisotopes6. Company Profiles6.1 Actinium Pharmaceuticals, Inc.6.2 Advanced Medical Isotope Corporation6.2.1 AMICs Medical Isotope Products6.3 Bio-Nucleonics6.3.1 Strontium Chloride Sr896.3.2 Rubigen6.4 Bracco Diagnostics, Inc.6.4.1 CardioGen-826.5 Covidien, PLC6.5.1 Covidiens Nuclear Medicine Products6.5.1.1 Duosafe6.5.1.2 Indium In-111 chloride sterile solution6.5.1.3 Octreoscan6.5.1.4 Sodium Iodide I-131 Capsules6.5.1.5 Technescan HDP6.5.1.6 Thallous Chloride Tl 2006.5.1.7 Ultra-Technekow Dry-Top Eluting (DTE)6.5.1.8 Gallium Citrate Ga-67 Injection6.5.1.9 Tc 99m Sestamibi6.5.1.10 Sodium iodide I-1236.5.1.11 Technescan MAG36.5.1.12 Technescan PYP6.5.1.13 Ultratag RBC6.6 DRAXIMAGE, Inc.6.7 FluoroPharma, Inc.6.7.1 FluoroPharmas technology6.7.1.1 CardioPET6.7.1.2 BFPET6.7.1.3 VasoPET6.8 GE Healthcare6.8.1 GEs PET and PET-Related Products6.8.1.1 CardIQ Fusion6.8.1.2 CardIQ Physio
    • 6.8.1.3 Dynamic VUE6.8.1.4 MINItrace6.8.1.5 PETtrace6.8.1.6 Discovery PET/CT 6006.8.1.7 Discovery PET/CT 6906.8.1.8 Discovery VCT6.8.1.9 Discovery STE6.8.1.10 Discovery ST6.8.1.11 Optima PET/CT 5606.9 Lantheus Medical Imaging, Inc.6.9.1 Selected Products from Lantheus6.9.1.1 Cardiolite (Kit for Technetium Tc99m Sestamibi for Injection)6.9.1.2 Technetium Tc 99m Generator6.10 MIM Software Inc.6.10.1 MIMfusion6.10.2 MIMcardiac6.10.3 MIMviewer6.10.4 MIM Storage Server6.11 Neusoft Medical Systems Co., Ltd.6.11.1 Truesight PET6.11.2 BeyondImage Workstation (BW)6.11.3 CardioCARE6.11.4 PETCare6.12 Nordion Inc.6.12.1 Nordions Business Strategy6.12.2 Nordions Medical Isotope Business Priorities6.12.3 Nordions Sterilization Technologies Business Priorities6.12.4 Nordions Medical Isotopes6.13 Numa, Inc.6.13.1 NumaLink6.13.2 NumaList6.13.3 NumaList Plus6.13.4 NumaStore6.13.5 NumaRead6.13.6 NumaServer6.13.7 NumaManage6.13.8 Numas Core Lab system6.14 Philips Healthcare6.14.1 Ingenuity TF PET/CT6.14.2 GEMINI TF Big Bore PET/CT6.14.3 GEMINI TF PET/CT6.14.4 GEMINI TF Ready PET/CT6.14.5 GEMINI LXL6.15 Positron Corporation
    • 6.15.1 Attrius6.15.2 Cardio-Assist6.15.3 Radiopharmaceuticals6.15.4 Tech-Assist6.16 Siemens Healthcare6.16.1 Biograph TruePoint (16-slice PET/CT)6.16.2 Syngo.via6.17 Thinking Systems Corporation6.17.1 MDStation6.17.2 MDStation for PET and PET/CTLIST OF FIGURESFigure 2.1: Illustration of the SMART ScannerFigure 2.2: Illustrations of PET, CT and Fused PET/CT ScansFigure 2.3: Collision of a Positron and Electron and the Creation of Two Resultant GammaRaysFigure 2.4: Discharge of Two Gamma Rays at 180 DegreesFigure 2.5: A Sinogram with Coincidence LinesFigure 2.6: PET Images Viewed in Axial, Coronal and Sagittal PlanesFigure 2.7: Block Diagram of PET ScannerFigure 2.8: Principles of Operation of a Combined PET/CT ScannerFigure 2.9: Two Scanners Mounted Back-to-Back for Sequential AcquisitionFigure 2.10: Full Integration of a Whole-Body PET/MRI SystemFigure 3.1: Projection for Global Cancer Deaths, 2010-2030Figure 3.2: Projected Cost of Cardiovascular Disease, 2010-2030Figure 3.3: CVD: The Single Largest Killer in AdultsFigure 3.4: Prevalence of CVD in Four of the Ethnic Groups in the U.S.Figure 3.5: Percentage Breakdown of Deaths from CVD in the U.S.Figure 3.6: Costs of Major CVD Types in the U.S.Figure 3.7: Increasing Number of Heart Failures in Europe, 2010-2020Figure 3.8: CVD in Middle Income CountriesFigure 3.9: CVD in Developed CountriesFigure 5.1: Global Market for Medical Imaging Equipment by Geography, 2010Figure 5.2: Global Medical Imaging Market Share by Modality, 2010Figure 5.3: Global Cancer Cases, 2009-2020Figure 5.4: U.S. Spending on Cancer, 2010-2020Figure 5.5: Spending on Cancer in U.K., 2010-2020Figure 5.6: Percent Comparison of Spending on Cancer, 2010Figure 5.7: Volume Distribution in Cancer Imaging in the U.S.Figure 5.8: Distribution of Outpatient Cancer Services in the U.S.Figure 5.9: Global Market for Diagnostic Imaging Equipment for Oncology, 2010-2017Figure 5.10: PET/CTs Share in Oncology Imaging Market, 2010-2017Figure 5.11: Percent PET/CT Imaging by Cancer Type
    • Figure 5.12: Percent Share of Oncology, Cardiology and Neurology in PET/CT ScanningFigure 5.13: Nuclear Cardiology Procedures for 100,000 of Population per Year forDeveloping vs. Developed CountriesFigure 5.14: Future of Nuclear Cardiology in 2014Figure 5.15: Approximate Use of Cardiac Diagnostic Testing, U.S.Figure 5.16: Utilization of Nuclear Cardiology in Developed CountriesFigure 5.17: Utilization of Nuclear Cardiology in Latin AmericaFigure 5.18: Utilization of Nuclear Cardiology Procedures in Asia/OceaniaFigure 5.19: Utilization of Nuclear Cardiology in AfricaFigure 5.20: Global Market for PET Services, 2010-2017Figure 5.21: Projected Market Share of PET and SPECT in 2020Figure 5.22: Growth Rate for SPECT and PET, 2011-2014Figure 5.23: Number of Cameras: SPECT Switching to PET, 2011-2014Figure 5.24: Top Ten Body Sites of Cancer for Men in the U.S.Figure 5.25: Top Ten Body Sites of Cancer in U.S. WomenFigure 5.26: U.S. PET and PET/CT Patient Studies in Oncology, 2001-2008Figure 5.27: U.S. PET and PET/CT Patient Studies in Cardiology, 2001-2008Figure 5.28: U.S. PET and PET/CT Patient Studies in Neurology, 2001-2008Figure 5.29: PET-Only Sites/Studies vs. PET/CT Sites/StudiesFigure 5.30: Trends in PET Procedure Volume in Finger Lakes Region, 2003-2009Figure 5.31: U.S. PET Utilization by Body Site, 2009Figure 5.32: U.S. PET Utilization Rate, 2003-2009Figure 5.33: Approximate U.S. Sales of SPECT & SPECT/CT and PET & PET/CT, 2005-2009Figure 5.34: Cardiac PET HOPPS payments, 2008-2011Figure 5.35: U.S. Market for PET, 2010-2017Figure 5.36: Percent Self-Reported Heart Disease By Age GroupFigure 5.37: Installed Units of PET in E.U, 2002-2013Figure 5.38: Installed Units of PET/CT in E.U., 2002-2013Figure 5.39: Growth of PET and PET/CT Examinations in E.U., 2002-2013Figure 5.40: Location of PET Centers in EuropeFigure 5.42: PET Studies per Million Populations in EuropeFigure 5.41: Evolution of Cyclotron in EuropeFigure 5.43: Location of PET Cameras in EuropeFigure 5.44: Growth of Cyclotron Units in Europe, 2000-2010Figure 5.45: European Nuclear Imaging Market Share by Geography, 2010Figure 5.46: European Market for PET/CT, 2010-2017Figure 5.47: Nuclear Imaging Market in Germany, 2010-2017Figure 5.48: Nuclear Imaging System Market in France, 2010-2017Figure 5.49: Nuclear Imaging System Market in U.K., 2010-2017Figure 5.50: Nuclear Imaging System Market in Italy, 2010-2017Figure 5.51: Number of Installed Bases in Nuclear Medicine in IndiaFigure 5.52: Nuclear Medicine Equipment Market in IndiaFigure 5.53: Indian Nuclear Medicine Equipment Market by ApplicationFigure 5.54: Global Demand Trend for Mo-99/Tc-99m
    • Figure 5.55: Global Market for Mo-99 by Geography/Country, 2009Figure 5.56: Global Demand for Tc-99m (48 Million Doses/Year), 2009Figure 5.57: Composition of Nuclear Medicine Procedures Utilizing Tc-99mFigure 5.58: Global Demand for Mo-99 and Tc-99Figure 5.59: U.S. FDG Sales, 2010-2017Figure 5.60: U.S. Sales of Diagnostic Radiopharmaceuticals, 2007-2014Figure 5.61: U.S. PET Procedure Volume Increase, 2007-2015Figure 5.62: U.S. Sales of Fluorodeoxyglucose (FDG), 2007-2015Figure 5.63: U.S. Export Share in Radioisotopes by Major Markets, 2007Figure App. 2.1: Number of Global Nuclear Medicine Procedures Using for 99mTC/99Mo,1990-2020Figure App. 2.2: Growth of 99Mo Requirements, 1990-2020Figure App. 2.7: Quantity of 99Mo Delivered to End-Users by Geography, 2007Figure App. 2.8: Regional Shares of Reactor Production of 99Mo, 2007Figure App. 2.9: Regional Shares of Reactor Production and Requirements of 99Mo, 2007Figure App. 2.10: Regional Shares of Reactor Production and Requirements of 99Mo, 2007Figure App. 5.1: Types of Nuclear Medicine Procedures that Can be Done Using Tc-99mFigure App. 5.2: The basic linear supply chain for Tc-99mFigure App. 5.3: North American Supply Chain for Tc-99mFigure App. 5.4: Global Supply Chains for Tc-99mFigure App. 5.5: Global Market Share by Reactor for Tc-99mFigure App. 6.1: Growth in Allowed Services and Allowed Charges for Advanced ImagingPaid Under the MPFS, 1995 to 2005Figure App. 6.2: Percentage of Total Growth in Allowed Services by Imaging Modality, 1995to 2005Figure App. 6.3: Percentage of Total Growth in Allowed Charges by Imaging Modality, 1995to 2005Figure App. 6.4: Growth in Advanced Imaging Utilization Rates, 1995 to 2005LIST OF TABLESTable 2.1: Comparison of PET with Other Imaging ModalitiesTable 2.3: Average Adult PET and PET/CT Scan TimesTable 2.4: Applications of PET in OncologyTable 3.1: Applications of PET in CardiologyTable 3.2: Characteristics of SPECT vs. PET in Cardiac ImagingTable 3.3: List of Common PET Tracers Used in the Evaluation of Neurological DisordersTable 4.1: Common PET RadioisotopesTable 4.2: Examples of PET RadiopharmaceuticalsTable 4.3: Estimated Radiation Dose with Intravenous Administration of FDG in a 70-kgPatientTable 4.4: PET Radiopharmaceuticals: Their Applications, Mechanisms of Uptake andLocalizationsTable 4.5: FDA-Approved Radiopharmaceuticals as of August 3, 2010
    • Table 5.1: U.S. PET Locations and ExamsTable 5.2: Utilization by Payment Type in Finger Lake Region, 2009Table 5.3: Effect of Coverage Changes on Oncologic Uses of FDG PETTable 5.4: Volume Outlook for Outpatient Imaging, 2005-2015Table 5.5: Medicare Reimbursement for PET ProceduresTable 5.6: Publicly Funded PET Scanners in Canada, 2009Table 5.7: Funding for PET Scans (Period prior to October 1, 2009)Table 5.8: Alberta IndicationsTable 5.9: Estimated Ontario New Cancer Cases, 2009Table 5.10: Publicly Funded PET Scanners in Ontario 2009Table 5.11: Approved International Indications for Clinical Use of 18F-FDGTable 5.12: Availability of Publicly Funded Clinical PET Scanning in CanadaTable 5.13: European PET, PET/CT, PET/NM InstallationsTable 5.14: Typical Radiation DosesTable 5.15: PET Scanning Facilities in EuropeTable 5.16: PET Scanning Facilities in EnglandTable 5.17: Typical Radiation DosesTable 5.18: Capital Costs for a PET Center with a Distant Supply of TracerTable 5.19: Staff Costs per Annum for Imaging with a Distant Supply of TracerTable 5.20: Fixed Costs per Annum for Imaging with a Distant Supply of TracerTable 5.21: Variable Costs per Annum for Imaging with a Distant Supply of TracerTable 5.22: Total Capital Scanning Costs for Imaging and Radiotracer Production FacilityTable 5.23: Capital Costs for Full Production of Radiotracer within an Imaging and FullProduction of Tracer FacilityTable 5.24: Staff Costs per Annum for an Imaging and Full Production of Tracer FacilityTable 5.25: Staff Costs for the Cyclotron and Radiochemistry Within an Imaging and FullProduction of Tracer UnitTable 5.26: Fixed Radiotracer Production CostsTable 5.27: Variable Scanning CostsTable 5.28: Radiotracer Production Variable CostsTable 5.29: Medical Cyclotrons in IndiaTable 5.30: PET/CT Scanner Profile in IndiaTable 5.31: PET/CT Scanners by Number of Slices in IndiaTable 5.32: Major current 99Mo producing reactorsTable 5.33: Characteristics of Positron Emitting Tracers Used in PET Perfusion ImagingTable 5.34: Worldwide Production Capacity of 99Mo, 2009Table 5.35: Small Scale Production of 99Mo, 2010Table 5.36: Nuclear Medicine Procedures that Use Tc-99mTable 5.37: Radiopharmaceuticals of Clinical Use in EuropeTable 5.38: Useful Radionuclides for Molecular ImagingTable 5.39: U.S. Shipments, Consumption and Trade of RadioisotopesTable 5.40: U.S. Exports, Imports and Trade Balance by Selected Countries, 2003-2007Table 5.41: U.S. Imports of Radioisotopes for Consumption, 2003-2007Table 6.1: Actiniums Product Pipeline
    • Table App. 1.1: Global Reactor LandscapeTable App. 1.2: Global Share of Nuclear Medicine by Reactor, 2009Table App. 2.1: Radionuclides for Which Supply is Believed to be in Jeopardy in 2010-2020Table App. 3.1: Imaging Properties of PET CrystalsTable App. 3.2: Average adult PET and PET/CT Scan TimesTable App. 3.3: Common PET RadioisotopesTable App.3.4: Examples of PET RadiopharmaceuticalsTable App. 4.1: Research Reactors Producing RadioisotopesTable App. 4.2: Estimated Worldwide Value of Radioisotope ProductionTable App. 6.1: Ten Most Frequently Billed Advanced Imaging Procedure Codes, 2005Table App. 6.2: Growth in Allowed Charges for Advanced Imaging Under the MPFS by Year,1995-2005Table App. 6.3: CT Services Billed Under the MPFS by Provider Specialty, 1995-2005Table App. 6.4: PET Services Billed Under the MPFS by Provider Specialty, 1995-2005About Us:ReportsnReports is an online library of over 100,000+ market research reports and in-depth marketresearch studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support toour customers. Get in touch with us for your needs of market research reports.Follow us on Twitter: http://twitter.com/marketsreportsOur Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689Contact:Mr.Priyank7557 Rambler road,Suite727,Dallas,TX75231Tel: +1-888-989-8004E-mail: sales@reportsnreports.comhttp://www.reportsnreports.comVisit our Market Research Blog